You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 21, June 1, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Statistics and Research Methods
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Apstein refers to the Dutch GIPS 1 study as the "benchmark study" of GIK, yet this trial failed to demonstrate a significant benefit of GIK infusion in all randomized patients.1 Similarly, a presentation of the recently completed Dutch GIPS 2 study indicated no benefit of GIK on mortality or infarct size in patients with AMI treated early with primary PCI; in fact, the trial was stopped early by the safety monitoring committee because of a potentially higher mortality in the GIK group.2 These data are entirely consistent with the results of CREATE-ECLA,3 which was conducted largely in South America, India, and China, and suggest that interpretation of such trials should be based on their own relative merits, including internal and external validity, rather than on where the trial was conducted.

With regard to the timing of GIK administration, it is noteworthy that in the previous generation of . . . [Full Text of this Article]

Shamir R. Mehta, MD, MSc
smehta@mcmaster.ca

Salim Yusuf, MBBS, DPhil
McMaster University and Population Health Research Institute
Hamilton, Ontario

Rafael Diaz, MD; Ernesto Paolasso, MD
Estudios Cardiologicos Latinoamerica (ECLA)
Rosario, Argentina
for the CREATE-ECLA Steering Committee



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points
Goyal et al.
Diabetes and Vascular Disease Research 2008;5:276-284.
ABSTRACT  

Glucose, insulin, and acute myocardial infarction: reply
Goyal et al.
Eur Heart J 2006;27:2142-2143.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.